The BioIndustry Association (BIA) will be supporting our strategic opportunities and fundraising activities over the next 12 months.
The James Lind Alliance Priority Setting Partnership (PSP) seeks to understand what hearing and dementia research priorities people who are deaf, or have hearing loss or tinnitus, have.
We are really excited about a world-first clinical trial, to see whether gene therapy can provide hearing for children with severe to profound hearing loss due to a rare genetic condition.
Throughout her research career, Professor Karen Steel and her team have identified dozens of genes that are involved in hearing loss.
Hugh Strickland speaks about his experience of hearing loss and his hopes for future treatments.
On 2 September, we proudly hosted the 2023 Hearing Therapeutics Summit, in collaboration with University College London’s Ear Institute, and the UCLH National Institute of Health Research at University College London Hospital.
A new cell therapy that could repair damage to the auditory nerve and improve hearing could hold fresh hope for people living with hearing loss.
A new drug proven to lower the risk of hearing loss in children with cancer by up to 42% awaiting approval in the UK.
The first medication to prevent hearing loss, caused by commonly used antibiotics, has been developed by biotechnology company, Oricula Therapeutics.
RNID is delighted to join forces with the University College London to run the 2023 Hearing Therapeutics Summit this Septem